Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Aberdeen
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Aberdeen, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca14 Eli Lilly and Company5 AbbVie5 Merck Sharp & Dohme LLC5 Boehringer Ingelheim3
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Aberdeen

91 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Newquay, Poole, Thetford, West Bromwich, Chichester, West Kirby, Aberdeen, Ashton-under-Lyne
2026-10-26
Not yet open
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
NCT07808151Colon Cancer, Microsatellite Stable (MSS) Colon Cancer, Proficient Mismatch Repair (pMMR) Colon Cancer
DrugsPorustobart·Keytruda·Pembrolizumab
Solstice Oncology, Inc.
Phase 2
100
Aberdeen, Cardiff, Glasgow, Leeds, London
2026-09-30
Recruiting
AstraZeneca
Phase 3
2,800
Aberdeen, Bristol, Cardiff, Dundee, Glasgow, London, Swansea
2026-09-01
Recruiting
AstraZeneca
Phase 3
7,000
Aberdeen, Cardiff, Corby, Coventry, Dundee, Glasgow, Leicester, Liverpool
2026-08-21
Recruiting
VectivBio AG
Phase 3
124
London, Aberdeen, Birmingham, Salford
2026-08
Recruiting
AstraZeneca
Phase 3
1,200
Aberdeen, Addlestone, Banbury, Bristol, Edinburgh, Hounslow, Penzance, Poole
2026-07-06
Recruiting
Prilenia
Phase 3
400
Aberdeen, Birmingham, Cardiff, Liverpool, Newcastle upon Tyne
2026-07-01
Recruiting
Ipsen
Phase 3
350
Frimley, London, Norwich, Oxford, Cottingham, Aberdeen, Birmingham, Glasgow
2026-05-14
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Aberdeen, Manchester, London
2026-05-06
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Exeter, Aberdeen, Cambridge, Cardiff, Glasgow, Leeds, London, Oxford
2026-03-24
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Blackpool, Aberdeen, Antrim, Bristol, Dundee, Hounslow, Hull, Nuneaton
2026-03-23
Recruiting
Bristol-Myers Squibb
Phase 3
750
Aberdeen, Middlesbrough, Norwich, Sutton, Cambridge, Cardiff, Guildford, London
2026-03-12
Recruiting
Eli Lilly and Company
Phase 3
300
Aberdeen, Birmingham, Bristol, Cambridge, Cardiff, Oxford, Southampton
2026-02-05
Recruiting
Exciva GmbH
Phase 2/3
300
Edinburgh, Aberdeen
2026-02-02
Recruiting
Regeneron Pharmaceuticals
Phase 3
915
Aberdeen, Truro, Plymouth, Norwich, Birmingham, Dundee
2026-01-02
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Oxford, Aberdeen, Derby, Lincoln, London, Southampton, Sutton
2025-11-25
Recruiting
Summit Therapeutics
Phase 3
600
Canterbury, London, Aberdeen, Edinburgh, Liverpool, Manchester
2025-11-18
Recruiting
Eli Lilly and Company
Phase 3
4,500
Aberdeen, Clifton, Enfield, Glasgow, Ipswich, Liverpool, London, Newcastle upon Tyne
2025-10-15
Active, closed
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
10,000
Aberdeen, Bristol, High Wycombe, Peterborough, Truro, Edinburgh, Birmingham, Blackpool
2025-09-25
Recruiting
Novartis Pharmaceuticals
Phase 2
407
Edinburgh, Oxford, Aberdeen, London, Newcastle upon Tyne, Salford, Southampton
2025-08-07
Recruiting
AstraZeneca
Phase 3
700
Aberdeen, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Greater London, Guildford
2025-08-06
Recruiting
Merck Sharp & Dohme LLC
Phase 2
340
Aberdeen, Edinburgh, Southampton, London, Oxford, Bath, Birmingham
2025-07-16
Recruiting
Takeda
Phase 3
225
Aberdeen, Rhyl, Leicester, Lincoln, High Heaton, Sunderland, Birmingham, Cambridge
2025-05-06
Recruiting
BeOne Medicines
Phase 3
250
Aberdeen, Birmingham, Bournemouth, London, Southampton
2025-04-10
Recruiting
AstraZeneca
Phase 3
11,300
Aberdeen, Chesterfield, Dundee, Gatley, Glasgow, London, Norwich, Penzance
2025-03-14
Recruiting
Bristol-Myers Squibb
Phase 3
530
Central Middlesbrough, Aberdeen, Manchester, Metropolitan Borough of Wirral
2025-02-25
Recruiting
AbbVie
Phase 3
420
London, Gillingham, Aberdeen, Leeds, Stockport
2025-02-13
Active, closed
Zura Bio Inc
Phase 2
80
Aberdeen, Bath, Dundee, Leeds, Liverpool, London, Stoke-on-Trent
2025-02-06
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Aberdeen, Birmingham, Cambridge, Glasgow, Leeds, Liverpool, London, Manchester
2025-01-28
Recruiting
OSE Immunotherapeutics
Phase 3
363
Leicester, Manchester, Metropolitan Borough of Wirral, Sutton, Aberdeen
2024-12-03
Recruiting
AstraZeneca
Phase 3
1,160
Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne
2024-11-18
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Aberdeen, Bristol, Camberley, Derby, Edgbaston, Birmingham, Exeter, Glasgow, Hull
2024-11-12
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Aberdeen, Ashton in Makerfield, Bristol, Camberley, Dagenham, Edgbaston, Birmingham, Edgware, Enfield, London
2024-10-14
Active, closed
Ipsen
Observational
424
Aberdeen, Belfast, Birmingham, Bradford, Hull, London, Newcastle, Nottingham
2024-10-14
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
982
Bebington, Guildford, Aberdeen, Birmingham, Bristol, Cambridge, Glasgow, Liverpool
2024-07-31
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
89bio, Inc.
Phase 3
762
Aberdeen, Bristol, Leeds, London, Oxford, Plymouth, Port Talbot, Portsmouth
2024-05-24
Active, closed
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)
DrugsKeytruda·Pembrolizumab
Inhibrx Biosciences, Inc
Phase 2/3
410
Chelsea, Northwood, Newcastle upon Tyne, Sutton, Aberdeen, Cambridge, Manchester, Norwich
2024-05-14
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Aberdeen, Birmingham, Bristol, Edinburgh, Exeter, Lancaster, Leeds, London
2024-05-06
Active, closed
Eli Lilly and Company
Phase 3
10,000
Aberdeen, Birmingham, Bromborough, Coventry, Glasgow, Hull, Ipswich, Lancashire
2024-04-30
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Aberdeen, Birmingham, Boston, Bradford, Liverpool, London, Newport
2024-02-05
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsErbitux·Cetuximab
AVEO Pharmaceuticals, Inc.
Phase 3
410
Aberdeen, London, Nottingham, Sutton, Torquay
2024-01-11
Recruiting
Eli Lilly and Company
Phase 3
1,264
Aberdeen, Dundee, Huddersfield, Leeds, Manchester, Northwood, Sheffield, Wolverhampton
2023-12-21
Recruiting
AstraZeneca
Phase 3
1,145
Aberdeen, Cambridge, Hampshire, Leeds, London, Manchester, Metropolitan Borough of Wirral, Northwood
2023-12-14
Recruiting
Regeneron Pharmaceuticals
Phase 3
904
Aberdeen, Uxbridge
2023-12-13
Active, closed
AstraZeneca
Phase 3
1,898
Aberdeen, Birmingham, Cambridge, Glasgow, Guildford, London, Manchester, Newcastle upon Tyne
2023-11-21
Active, closed
Regeneron Pharmaceuticals
Phase 3
733
Truro, Uxbridge, Birmingham, Aberdeen
2023-11-14
Active, closed
AstraZeneca
Phase 3
5,511
Aberdeen, Burton-on-Trent, Cambridge, Derby, Guildford, Ipswich, Lancaster, Leeds
2023-10-05
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Ilford, Swinton, London, Aberdeen, Chertsey, Edinburgh, Leeds, Motherwell
2023-08-28
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Ilford, Swinton, Aberdeen, Chertsey, Leeds, Motherwell, Preston, Sheffield, SouthYorkshire
2023-07-11
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Aberdeen, Windsor, Derby, Bournemouth, Portsmouth, Stoke-on-Trent, Edinburgh, London
2023-06-22
By invitation
AbbVie
Phase 3
650
Aberdeen, Stockport
2023-06-05
Recruiting
AbbVie
Phase 3
450
London, Gillingham, Aberdeen, Stockport
2023-05-01
Active, closed
BeOne Medicines
Phase 2/3
178
Aberdeen, Derby
2023-04-17
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Aberdeen, Birmingham, Colchester, Liverpool, London, Middlesbrough, Norwich, Staffordshire
2023-03-29
Active, closed
Janssen Research & Development, LLC
Phase 3
12,523
Aberdeen, Airdrie, Bath, Bury, Cheltenham, Dartford, Doncaster, Dundee
2023-02-15
Active, closed
Ipsen
Phase 2
68
Aberdeen, Birmingham, Frimley, Glasgow, Hull, London
2022-12-29
Active, closed
AstraZeneca
Phase 3
1,350
Aberdeen, Cambridge, Cardiff, Cheltenham, Edinburgh, London, Manchester, Middlesbrough
2022-12-29
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2
87
Aberdeen, Edinburgh, London, Oxford
2022-11-07
Active, closed
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
Bayer
Phase 3
474
London, Liverpool, Glasgow, Redhill, Aberdeen
2022-10-14
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
410
Swindon, Aberdeen, Motherwell
2022-08-23
Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
DrugsAbraxane·Nab-paclitaxel·Gemcitabine
Panbela Therapeutics, Inc.
Phase 2/3
600
Aberdeen, London, Plympton
2022-08-08
Active, closed
Eli Lilly and Company
Phase 4
780
Aberdeen, Dundee, Ely, Plymouth, Hull, Leicester, Rotherham
2022-08-01
Active, closed
Pfizer
Phase 2
108
Aberdeen, Birmingham
2022-07-11
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Aberdeen, Truro, London-Camden
2022-01-14
Active, closed
Janssen Pharmaceutica N.V., Belgium
Observational
1,314
Aberdeen, Abergavenny, Airdrie, Barnet, Bath, Glasgow, Hull, Leeds
2021-08-25
Active, closed
Mirati Therapeutics Inc.
Phase 3
461
Aberdeen, Birmingham, Cambridge, Dorset, Glasgow, Kent, Leeds, London
2021-06-24
Active, closed
Incyte Corporation
Phase 3
899
Aberdeen, Bath, Birmingham, Bristol, London, Nottingham, Sutton, Wolverhampton
2021-05-11
Active, closed
Alfasigma S.p.A.
Observational
1,304
Aberdeen, Barnet, Coventry, Doncaster, Dundee, Edinburgh, Liverpool, London
2021-05-11
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Aberdeen, Plymouth, Newmarket, Glasgow, Nottingham, Oxford, Windsor
2021-04-08
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Aberdeen, Truro, Plymouth, Cottingham, London, Norwich, Swansea, Edinburgh
2021-03-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
747
Aberdeen, Bath, Nottingham, Southend, London, Northwood, Taunton, Swansea
2021-02-25
Active, closed
BioNTech SE
Phase 2/3
358
Aberdeen, Belfast, Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool
2021-01-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
Aberdeen, Dundee, Taunton, London, Manchester
2020-12-08
Active, closed
Medicago
Phase 2/3
30,918
Aberdeen, Birmingham, Bournemouth, Cardiff, Chelmsford, Chorley, Derby, Harrow
2020-11-19
Active, closed
AbbVie
Phase 3
531
Plymouth, Poole, London, Oxford, Cardiff, Aberdeen, Birmingham, Bristol
2020-09-10
Active, closed
AstraZeneca
Phase 3
818
Aberdeen, Bournemouth, Bristol, Cardiff, Cheltenham, London, Manchester, Sutton
2020-04-16
Active, closed
BeOne Medicines
Phase 3
955
Aberdeen, Birmingham, Bournemouth, Canterbury, Glasgow, Greater Manchester, Headington, Leeds
2020-01-16
Active, closed
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
NCT04056247Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer
OncoHost Ltd.
Observational
10,000
Aberdeen, Bournemouth, Bradford, Cheltenham, Haverfordwest, Northwood, Shrewsbury, South Shields
2019-10-01
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
665
Aberdeen, Leeds, London, Oxford, Sutton in Ashfield
2019-08-12
By invitation
Novo Nordisk A/S
Observational
60
Aberdeen, Cardiff, Manchester, Sheffield
2019-04-01
Active, closed
Celgene
Phase 3
363
Aberdeen, Bournemouth, Headington, Oxford, Lincoln, London, Manchester
2019-01-02
Active, closed
Exelixis
Phase 3
187
Birmingham, Bristol, London, Oxford, Aberdeen, Glasgow, Cardiff, Manchester
2018-10-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Aberdeen, Cambridge, Edinburgh, Manchester, Sheffield, Broomfield, Glasgow, Preston
2018-08-21
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Folinic acid·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Aberdeen, London, Sutton, Cambridge, Coventry, Dundee, Leeds, Manchester
2018-06-21
Active, closed
AstraZeneca
Phase 2
273
Aberdeen, Bristol, Cardiff, Durham, Edinburgh, Leicester, London, Manchester
2018-03-07
Active, closed
Tesaro, Inc.
Phase 1
729
Newcastle upon Tyne, Aberdeen, London, Manchester, Oxford, Sutton
2016-03-07
Active, closed
Geron Corporation
Phase 2/3
289
Leeds, Nottingham, Southampton, Aberdeen
2016-01-12
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Aberdeen, Birmingham, Bristol, Derby, Glasgow, Oxford, Plymouth, Preston
2015-11-19
Active, closed
AbbVie
Observational
1,446
Derby, Sheffield, London, Southampton, Glasgow, Carshalton, Aberdeen, Birmingham
2014-08-28
Active, closed
AstraZeneca
Phase 3
510
Aberdeen, London, Manchester, Nottingham, Sutton, Wolverhampton
2013-09-25
Rows per page Showing 1–91 of 91
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-uk/city/aberdeen

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 11 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 91 of those studies with a site in Aberdeen.

How many clinical trials are recruiting in Aberdeen?

44 of the 91 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:15 UTC sync. A further 2 have not yet opened recruitment, 43 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Aberdeen), 91 studies
PhaseStudiesRecruitingShare
Phase 3663872.5%
Phase 2/3949.9%
Phase 2828.8%
Observational606.6%
Phase 1101.1%
Phase 4101.1%

Most active sponsors

Lead sponsors with the most studies (Aberdeen)
Lead sponsorStudiesRecruiting
AstraZeneca148
AbbVie52
Eli Lilly and Company53
Merck Sharp & Dohme LLC53
BeOne Medicines31
Boehringer Ingelheim32
Bristol-Myers Squibb32
Ipsen31
Karuna Therapeutics, Inc., a Bristol Myers Squibb company33
Regeneron Pharmaceuticals32
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.